Meeting Highlights

The Advanced Practitioner Perspective

    SOHO 2020 Annual Meeting

    Allyson Price, MPAS, PA-C, on Predicting Drug Response in Acute Lymphoblastic Leukemia



    Watch Video

    Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses gene drug mapping, the future of precision medicine in leukemia, and the need for advanced practitioners to educate this patient population who may be new to the use of oral medications.

    SOHO 2020 Annual Meeting

    Allyson Price, MPAS, PA-C, on Immunotherapy for T-Cell ALL and T-NHL



    Watch Video

    Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses the Keynote lecture on two complex disease states, and the vital role advanced practitioners will play in managing patients on CAR-T therapies, and explaining graft-vs-host disease as well as other adverse events to their patients with hematologic malignancies.

    SOHO 2020 Annual Meeting

    Allyson Price, MPAS, PA-C, on Oral HMAs for Myelodysplastic Syndrome



    Watch Video

    Allyson Price, MPAS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses oral hypomethylating agents for MDS, and the implications for advanced practitioners helping patients adhere to the new regimens and maintain good quality of life.

    SOHO 2020 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on Myelofibrosis: New Therapies in Development



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses agents in phase III studies (both ongoing and planned), how the treatment landscape for myelofibrosis is changing, and what advanced practitioners need to know about managing adverse events, drug mechanisms of action, and staying up to date on the pipeline.

    SOHO 2020 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on Multiple Myeloma: Managing Early Relapse



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses new drug combinations to treat multiple myeloma, the challenges of managing relapsed and refractory disease, and the role that advanced practitioners need to play in educating patients about individualized treatments.

    SOHO 2020 Annual Meeting

    Lisa Nodzon, PhD, ARNP, AOCNP, on CLL: Measuring Residual Disease



    Watch Video

    Lisa Nodzon, PhD, ARNP, AOCNP, of Moffitt Cancer Center, discusses the progress made in treating chronic lymphocytic leukemia, the clinical implications of undetectable minimal residual disease in blood and bone marrow, and how advanced practitioners can help patients better understand their disease to weigh their treatment options.

    SOHO 2020 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Relapsed or Refractory Hodgkin Lymphoma: Integrating Novel Agents



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses what advanced practitioners need to know about integrating brentuximab vedotin and PD-1 blockade earlier in the care of patients with Hodgkin lymphoma, the optimal timing of novel agents as well as new agents showing promise, and combinations that may improve outcomes.

    SOHO 2020 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Peripheral T-Cell Lymphoma: Managing Relapsed Disease



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses insights for advanced practitioners on the many facets of treating peripheral T-cell lymphoma, including stem cell transplants, single agents vs combination chemotherapies, and disease targets.

    SOHO 2020 Annual Meeting

    Kelly Valla, PharmD, BCOP, on Cellular Therapy: New CAR Designs



    Watch Video

    Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, discusses next-generation CAR T cells and what advanced practitioners need to understand about enhanced cytotoxicity and increased persistence of the cells, endogenous anti-tumor immunity, and the immunosuppressive tumor microenvironment.

    ASH Annual Meeting

    Sandra E. Kurtin, PhD, ANP-C, AOCN, on Multiple Myeloma in Older Patients: Isatuximab With Pomalidomide and Dexamethasone



    Watch Video

    Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses data from the ICARIA-MM trial that show adding isatuximab to pomalidomide and dexamethasone improved progression-free survival, overall survival, overall response rate, and very good partial response rate in older patients (65 years and older) with relapsed/refractory multiple myeloma (Abstract 1893).

    ASH Annual Meeting

    Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax



    Watch Video

    Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses a currently enrolling phase III trial on a new strategy to decrease exposure time to ibrutinib, which has the potential to change the standard of care for patients 70 years or older with previously untreated chronic lymphocytic leukemia (Abstract 1751).

    ASH Annual Meeting

    Amy Pierre, ANP-BC, on Multiple Myeloma: Autologous Stem Cell Transplant in Older Patients



    Watch Video

    Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses study findings on the decreased use of autologous stem cell transplant in older patients with multiple myeloma, despite the therapy’s significant survival benefit. The study suggests factors that make it more likely patients would forgo the treatment (Abstract 2195).

    ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on MDS: MEDALIST Trial of Luspatercept to Treat Anemia



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings that showed most patients with lower-risk myelodysplastic syndrome treated with luspatercept, a first-in-class erythroid maturation agent, achieved independence from red blood cell transfusions and/or hematologic improvement (Abstract 841).

    ASH Annual Meeting

    Sandra E. Kurtin, PhD, ANP-C, AOCN, on Treating CLL in the Community Setting: Early Discontinuation of First-Line Ibrutinib



    Watch Video

    Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the findings of a retrospective study that assessed the use of first-line ibrutinib for chronic lymphocytic leukemia in the United States. Although the agent was increasingly used in this setting, early discontinuation was more common than reported, suggesting clinical decision support tools and care delivery approaches should be explored (Abstract 797).

    ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on MDS: Oral Rigosertib and Injectable Azacitidine



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses data that show rigosertib and azacitidine may provide a potential new first-line treatment for patients with high-risk myelodysplastic syndrome (Abstract 4268).

    ASH Annual Meeting

    Sara Tinsley, PhD, APRN, AOCN, on CLL: Therapies After Venetoclax Discontinuation



    Watch Video

    Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses study findings suggesting that BTK inhibitors in naive or previously responsive patients with chronic lymphocytic leukemia and allogeneic hematopoietic stem cell transplantation following venetoclax appear to be effective strategies with durable responses. The data indicate a number of effective regimens for patients after treatment with venetoclax, providing support for using venetoclax earlier in the course of CLL (Abstract 502).

    ASH Annual Meeting

    Sandra E. Kurtin, PhD, ANP-C, AOCN, on AML in First Remission: QUAZAR Trial of Oral Azacitidine



    Watch Video

    Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase III findings on oral azacitidine, the first treatment used in the maintenance setting shown to improve both overall and disease-free survival in patients with acute myeloid leukemia that is in remission following induction chemotherapy (Abstract LBA-3).

    ASH Annual Meeting

    Amy Pierre, ANP-BC, on Multiple Myeloma: CANDOR Trial of Carfilzomib, Dexamethasone, and Daratumumab



    Watch Video

    Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings that suggest the combination of carfilzomib, dexamethasone, and daratumumab represents an efficacious new regimen for patients with relapsed or refractory disease, including those who are refractory to lenalidomide (Abstract LBA-6).

    ASH Annual Meeting

    Lindsey M. Lyle, MS, PA-C, on AML: Safety Analysis of Glasdegib



    Watch Video

    Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses the use of glasdegib in addition to intensive or nonintensive chemotherapy in patients with acute myeloid leukemia (Abstract 2732).

    ASH Annual Meeting

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Myeloid and Lymphoid Leukemias: A Dual Treatment Strategy



    Watch Video

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the dual inhibition of Bruton’s tyrosine kinase and BCL2; with the combination of venetoclax and ibrutinib, this drug combination may have broad therapeutic indications (Abstract 214).

    ASH Annual Meeting

    Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Results From the Tourmaline-MM3 Trial



    Watch Video

    Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on maintenance therapy with the oral proteasome inhibitor ixazomib, which significantly prolonged progression-free survival following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma (Abstract 301).

    ASH Annual Meeting

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, on Treatment of CLL/SLL: 7-Year Follow-up Data



    Watch Video

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses phase Ib/II study findings on single-agent ibrutinib in the first-line and relapsed or refractory settings for chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 3133).

    ASH Annual Meeting

    Lindsey M. Lyle, MS, PA-C, on AML: Early Findings on Quizartinib and Milademetan



    Watch Video

    Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses preclinical study findings on synergistic antileukemic activity with a combination of the FLT3 inhibitor quizartinib and the MDM2 inhibitor milademetan in FLT3-ITD–mutant/p53 wild-type acute myeloid leukemia models (Abstract 2720).

    ASH Annual Meeting

    Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Results From the STORM Study



    Watch Video

    Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses study findings on pentarefractory multiple myeloma and the responses to oral selinexor plus low-dose dexamethasone (Abstract 598).

    ASH Annual Meeting

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, on CLL: Results From the MURANO Study



    Watch Video

    Sandra E. Kurtin, PhDc, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the first phase III prospective data on the impact of minimal residual disease on the long-term clinical outcomes with venetoclax plus rituximab vs bendamustine plus rituximab in chronic lymphocytic leukemia (Abstract 695).

    ASH Annual Meeting

    Lindsey M. Lyle, MS, PA-C, on AML: Results From an Early Phase Dose-Escalation and Dose-Expansion Trial



    Watch Video

    Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses study findings on venetoclax in combination with hypomethylating agents, which induced rapid, deep, and durable responses in patients with acute myeloid leukemia who are ineligible for intensive therapy (Abstract 285).

    ASH Annual Meeting

    Josh D. Epworth, MSN, ARNP, on Multiple Myeloma: Early Results From the PAVO Trial



    Watch Video

    Josh D. Epworth, MSN, ARNP, of the University of Washington Medical Center, discusses safety and efficacy data on subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma (Abstract 1995).


Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.